熱門資訊> 正文
默克公司Keytruda标签在美国扩大，用于间皮瘤
2024-09-18 19:08
- Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination therapy for mesothelioma, a cancer in the linings of internal organs.
- Accordingly, Keytruda will be available in the U.S. for use with pemetrexed and platinum chemotherapy as a first-line option for adults with unresectable advanced or metastatic malignant pleural mesothelioma.
- The decision was based on data from Merck's (MRK) Phase 2/3 KEYNOTE-483 trial, which demonstrated that Keytruda plus chemotherapy improved key cancer therapy metrics such as overall survival compared to chemotherapy alone with a statistically significant effect.
- The anti-PD1 therapy is approved for more than 41 indications in the U.S., and the latest approval marks its first indication in malignant pleural mesothelioma.
More on Merck
- Merck Appears Ready To Return To June Highs (Technical Analysis)
- Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
- Updating Walmart, Merck And Nike Post-Earnings
- Merck, Daiichi post late-stage trial win for novel lung cancer therapy
- BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
